[DOT 2017] Differentiated Receptor Pharmacology of Imipridone ONC201: The First DRD2 Antagonist in Clinical Development for Oncology

[DOT 2017] Differentiated Receptor Pharmacology of Imipridone ONC201: The First DRD2 Antagonist in Clinical  Development for Oncology
Version:
20770

File Name/Number:
2017 DOT

Year:
2017

ONC201, founding member of the imipridone class of compounds, has demonstrated evidence of tumor shrinkage along with exceptional safety in recurrent glioblastoma patients. In this study, we identified and characterized a previously unknown binding target of ONC201.